Switch to:
Also traded in: Brazil, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.40
CELG's Cash to Debt is ranked lower than
89% of the 941 Companies
in the Global Biotechnology industry.

( Industry Median: 49.71 vs. CELG: 0.40 )
Ranked among companies with meaningful Cash to Debt only.
CELG' s Cash to Debt Range Over the Past 10 Years
Min: 0.27  Med: 1.88 Max: No Debt
Current: 0.4
Equity to Asset 0.20
CELG's Equity to Asset is ranked lower than
89% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. CELG: 0.20 )
Ranked among companies with meaningful Equity to Asset only.
CELG' s Equity to Asset Range Over the Past 10 Years
Min: -0.68  Med: 0.59 Max: 0.92
Current: 0.2
-0.68
0.92
Interest Coverage 6.25
CELG's Interest Coverage is ranked lower than
84% of the 367 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CELG: 6.25 )
Ranked among companies with meaningful Interest Coverage only.
CELG' s Interest Coverage Range Over the Past 10 Years
Min: 7.26  Med: 27.63 Max: 428.04
Current: 6.25
7.26
428.04
F-Score: 5
Z-Score: 3.61
M-Score: -2.33
WACC vs ROIC
12.40%
18.74%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 24.75
CELG's Operating margin (%) is ranked higher than
89% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: -73.78 vs. CELG: 24.75 )
Ranked among companies with meaningful Operating margin (%) only.
CELG' s Operating margin (%) Range Over the Past 10 Years
Min: -64.94  Med: 28.83 Max: 32.84
Current: 24.75
-64.94
32.84
Net-margin (%) 17.38
CELG's Net-margin (%) is ranked higher than
87% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: -75.29 vs. CELG: 17.38 )
Ranked among companies with meaningful Net-margin (%) only.
CELG' s Net-margin (%) Range Over the Past 10 Years
Min: -68.02  Med: 23.31 Max: 28.88
Current: 17.38
-68.02
28.88
ROE (%) 28.58
CELG's ROE (%) is ranked higher than
96% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -32.24 vs. CELG: 28.58 )
Ranked among companies with meaningful ROE (%) only.
CELG' s ROE (%) Range Over the Past 10 Years
Min: -48.42  Med: 21.32 Max: 33.02
Current: 28.58
-48.42
33.02
ROA (%) 7.28
CELG's ROA (%) is ranked higher than
88% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: -27.48 vs. CELG: 7.28 )
Ranked among companies with meaningful ROA (%) only.
CELG' s ROA (%) Range Over the Past 10 Years
Min: -38.07  Med: 11.43 Max: 15.8
Current: 7.28
-38.07
15.8
ROC (Joel Greenblatt) (%) 163.22
CELG's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 909 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. CELG: 163.22 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CELG' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -421.4  Med: 163.93 Max: 212.3
Current: 163.22
-421.4
212.3
Revenue Growth (3Y)(%) 21.60
CELG's Revenue Growth (3Y)(%) is ranked higher than
76% of the 492 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. CELG: 21.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CELG' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 20.6  Med: 40.60 Max: 240.6
Current: 21.6
20.6
240.6
EBITDA Growth (3Y)(%) 13.10
CELG's EBITDA Growth (3Y)(%) is ranked higher than
70% of the 506 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. CELG: 13.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CELG' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -37.3  Med: 26.60 Max: 297.9
Current: 13.1
-37.3
297.9
EPS Growth (3Y)(%) 5.50
CELG's EPS Growth (3Y)(%) is ranked higher than
63% of the 501 Companies
in the Global Biotechnology industry.

( Industry Median: -5.20 vs. CELG: 5.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CELG' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -60.8  Med: 23.65 Max: 113.8
Current: 5.5
-60.8
113.8
» CELG's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-07-23)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

CELG Guru Trades in Q2 2015

Ken Heebner 110,000 sh (New)
Louis Moore Bacon 50,000 sh (New)
Paul Tudor Jones 21,062 sh (+562.33%)
Jim Simons 1,006,838 sh (+136.57%)
RS Investment Management 106,224 sh (+9.09%)
Pioneer Investments 3,523,050 sh (+1.38%)
Lee Ainslie 2,230 sh (unchged)
Murray Stahl 5,000 sh (unchged)
Mairs and Power 1,776 sh (unchged)
Stanley Druckenmiller Sold Out
Ronald Muhlenkamp Sold Out
Ray Dalio Sold Out
Ken Fisher 224,399 sh (-2.40%)
Mario Gabelli 24,265 sh (-2.71%)
Joel Greenblatt 7,778 sh (-56.76%)
» More
Q3 2015

CELG Guru Trades in Q3 2015

John Burbank 174,768 sh (New)
Murray Stahl 8,000 sh (+60.00%)
Louis Moore Bacon 80,000 sh (+60.00%)
RS Investment Management 130,238 sh (+22.61%)
Mario Gabelli 29,325 sh (+20.85%)
Mairs and Power 2,086 sh (+17.45%)
Ken Fisher 244,564 sh (+8.99%)
Pioneer Investments 3,637,052 sh (+3.24%)
Ken Heebner Sold Out
Lee Ainslie 2,090 sh (-6.28%)
Joel Greenblatt 6,344 sh (-18.44%)
Paul Tudor Jones 8,020 sh (-61.92%)
Jim Simons 378,633 sh (-62.39%)
» More
Q4 2015

CELG Guru Trades in Q4 2015

Steven Cohen 537,800 sh (New)
Mairs and Power 2,681 sh (+28.52%)
Lee Ainslie 2,380 sh (+13.88%)
Pioneer Investments 3,675,883 sh (+1.07%)
Ken Fisher 245,460 sh (+0.37%)
Murray Stahl 8,000 sh (unchged)
Samuel Isaly 256,000 sh (unchged)
Jim Simons Sold Out
John Burbank Sold Out
Louis Moore Bacon Sold Out
Joel Greenblatt Sold Out
Mario Gabelli 29,270 sh (-0.19%)
RS Investment Management 129,300 sh (-0.72%)
Paul Tudor Jones 6,016 sh (-24.99%)
» More
Q1 2016

CELG Guru Trades in Q1 2016

Ray Dalio 4,100 sh (New)
Joel Greenblatt 68,917 sh (New)
Julian Robertson 228,840 sh (New)
Lee Ainslie 4,900 sh (+105.88%)
Pioneer Investments 3,821,415 sh (+3.96%)
Murray Stahl 8,000 sh (unchged)
Samuel Isaly 256,000 sh (unchged)
Mairs and Power Sold Out
Paul Tudor Jones Sold Out
Steven Cohen Sold Out
Mario Gabelli 27,144 sh (-7.26%)
RS Investment Management 111,048 sh (-14.12%)
Ken Fisher 198,160 sh (-19.27%)
» More
» Details

Insider Trades

Latest Guru Trades with CELG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:BIIB, NAS:GILD, NAS:AMGN, OTCPK:CSLLY, NAS:REGN, NAS:SHPG, NYSE:BXLT, NAS:ALXN, NAS:VRTX, NYSE:NVO, OTCPK:ALIOY, NAS:INCY, OTCPK:UCBJF, OTCPK:NVZMY, NAS:BMRN, NAS:GRFS, OTCPK:GMXAY, NAS:MDVN, NAS:JAZZ, NAS:ALKS » details
Traded in other countries:CLGN34.Brazil, CG3.Germany, CELG.Mexico, CELG.Switzerland, 0QYA.UK,
Celgene Corp is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.

Celgene Corp is incorporated in Delaware in 1986. The Company is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of new therapies designed to treat cancer and immune-inflammatory related diseases. The Company is engaged in new research and development designed to bring new therapies to market and involved in research in several scientific areas that may deliver proprietary next-generation therapies, targeting areas including intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies. The Company' commercial stage products include REVLIMID, VIDAZA, ABRAXANE, POMALYST, IMNOVID, THALOMID (inclusive of Thalidomide Celgene, ISTODAX and azacitidine for injection (generic version of VIDAZA). It owns and operates a manufacturing facility in Zofingen, Switzerland which produces the active pharmaceutical ingredient (API) for REVLIMID and THALOMID and have contracted with third-party contract manufacturers to provide backup API manufacturing services for these products. Manufacturing services for REVLIMID and THALOMID, which consist of formulation, encapsulation, packaging, warehousing and distribution, are performed at our drug product manufacturing facility in Boudry, Switzerland. The Company faces competition from Amgen, AstraZeneca, Bristol-Myers-Squibb, Eisai, Gilead, Johnson & Johnson, Novartis, Pharmacyclics, Roche/Genentech, Sanofi and Takeda, AbbVie, Amgen, Biogen Idec, Eisai, Johnson & Johnson, Merck, Pfizer and UCB S.A. Regulation by governmental authorities in the United States and other countries is a factor in the manufacture and marketing of pharmaceuticals and in its ongoing research and development activities.

Top Ranked Articles about Celgene Corp

Gilead and Celgene Among Biotechnology Stocks to Buy Industry contains at least 2 stocks that gurus are adding to their portfolios
The general biotechnology industry offers gurus many opportunities to increase their portfolio returns. Several biotech stocks, including Gilead Sciences Inc. (NASDAQ:GILD) and Celgene Corp. (NASDAQ:CELG), have positive financial outlooks. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 46.52
CELG's P/E(ttm) is ranked lower than
65% of the 250 Companies
in the Global Biotechnology industry.

( Industry Median: 28.83 vs. CELG: 46.52 )
Ranked among companies with meaningful P/E(ttm) only.
CELG' s P/E(ttm) Range Over the Past 10 Years
Min: 17.91  Med: 47.85 Max: 618.72
Current: 46.52
17.91
618.72
Forward P/E 17.04
CELG's Forward P/E is ranked higher than
63% of the 76 Companies
in the Global Biotechnology industry.

( Industry Median: 20.70 vs. CELG: 17.04 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 46.52
CELG's PE(NRI) is ranked lower than
65% of the 234 Companies
in the Global Biotechnology industry.

( Industry Median: 28.83 vs. CELG: 46.52 )
Ranked among companies with meaningful PE(NRI) only.
CELG' s PE(NRI) Range Over the Past 10 Years
Min: 17.82  Med: 47.71 Max: 482.6
Current: 46.52
17.82
482.6
Price/Owner Earnings (ttm) 41.87
CELG's Price/Owner Earnings (ttm) is ranked lower than
56% of the 133 Companies
in the Global Biotechnology industry.

( Industry Median: 32.22 vs. CELG: 41.87 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
CELG' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 15.44  Med: 44.03 Max: 1163.68
Current: 41.87
15.44
1163.68
P/B 14.70
CELG's P/B is ranked lower than
91% of the 1017 Companies
in the Global Biotechnology industry.

( Industry Median: 3.34 vs. CELG: 14.70 )
Ranked among companies with meaningful P/B only.
CELG' s P/B Range Over the Past 10 Years
Min: 4.02  Med: 9.27 Max: 23.65
Current: 14.7
4.02
23.65
P/S 8.07
CELG's P/S is ranked higher than
60% of the 799 Companies
in the Global Biotechnology industry.

( Industry Median: 11.64 vs. CELG: 8.07 )
Ranked among companies with meaningful P/S only.
CELG' s P/S Range Over the Past 10 Years
Min: 5.41  Med: 10.34 Max: 27.13
Current: 8.07
5.41
27.13
PFCF 34.12
CELG's PFCF is ranked lower than
61% of the 142 Companies
in the Global Biotechnology industry.

( Industry Median: 26.08 vs. CELG: 34.12 )
Ranked among companies with meaningful PFCF only.
CELG' s PFCF Range Over the Past 10 Years
Min: 14.96  Med: 35.68 Max: 2438.33
Current: 34.12
14.96
2438.33
POCF 30.14
CELG's POCF is ranked lower than
61% of the 199 Companies
in the Global Biotechnology industry.

( Industry Median: 22.99 vs. CELG: 30.14 )
Ranked among companies with meaningful POCF only.
CELG' s POCF Range Over the Past 10 Years
Min: 13.93  Med: 33.36 Max: 1407
Current: 30.14
13.93
1407
EV-to-EBIT 33.24
CELG's EV-to-EBIT is ranked lower than
68% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 21.76 vs. CELG: 33.24 )
Ranked among companies with meaningful EV-to-EBIT only.
CELG' s EV-to-EBIT Range Over the Past 10 Years
Min: -28.6  Med: 35.40 Max: 156.6
Current: 33.24
-28.6
156.6
EV-to-EBITDA 28.27
CELG's EV-to-EBITDA is ranked lower than
67% of the 305 Companies
in the Global Biotechnology industry.

( Industry Median: 18.58 vs. CELG: 28.27 )
Ranked among companies with meaningful EV-to-EBITDA only.
CELG' s EV-to-EBITDA Range Over the Past 10 Years
Min: -31.4  Med: 29.20 Max: 132.5
Current: 28.27
-31.4
132.5
PEG 2.41
CELG's PEG is ranked lower than
52% of the 92 Companies
in the Global Biotechnology industry.

( Industry Median: 2.23 vs. CELG: 2.41 )
Ranked among companies with meaningful PEG only.
CELG' s PEG Range Over the Past 10 Years
Min: 1.38  Med: 2.17 Max: 3.24
Current: 2.41
1.38
3.24
Shiller P/E 90.86
CELG's Shiller P/E is ranked lower than
70% of the 54 Companies
in the Global Biotechnology industry.

( Industry Median: 54.39 vs. CELG: 90.86 )
Ranked among companies with meaningful Shiller P/E only.
CELG' s Shiller P/E Range Over the Past 10 Years
Min: 90.84  Med: 146.38 Max: 3211
Current: 90.86
90.84
3211
Current Ratio 4.57
CELG's Current Ratio is ranked higher than
51% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. CELG: 4.57 )
Ranked among companies with meaningful Current Ratio only.
CELG' s Current Ratio Range Over the Past 10 Years
Min: 1.35  Med: 6.43 Max: 44.53
Current: 4.57
1.35
44.53
Quick Ratio 4.32
CELG's Quick Ratio is ranked higher than
51% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.24 vs. CELG: 4.32 )
Ranked among companies with meaningful Quick Ratio only.
CELG' s Quick Ratio Range Over the Past 10 Years
Min: 1.13  Med: 6.33 Max: 44.15
Current: 4.32
1.13
44.15
Days Inventory 369.48
CELG's Days Inventory is ranked lower than
89% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 128.52 vs. CELG: 369.48 )
Ranked among companies with meaningful Days Inventory only.
CELG' s Days Inventory Range Over the Past 10 Years
Min: 66.12  Med: 203.77 Max: 363.39
Current: 369.48
66.12
363.39
Days Sales Outstanding 53.52
CELG's Days Sales Outstanding is ranked higher than
58% of the 610 Companies
in the Global Biotechnology industry.

( Industry Median: 63.07 vs. CELG: 53.52 )
Ranked among companies with meaningful Days Sales Outstanding only.
CELG' s Days Sales Outstanding Range Over the Past 10 Years
Min: 43.42  Med: 57.78 Max: 71.28
Current: 53.52
43.42
71.28
Days Payable 190.02
CELG's Days Payable is ranked higher than
82% of the 449 Companies
in the Global Biotechnology industry.

( Industry Median: 60.55 vs. CELG: 190.02 )
Ranked among companies with meaningful Days Payable only.
CELG' s Days Payable Range Over the Past 10 Years
Min: 61.81  Med: 109.32 Max: 209.22
Current: 190.02
61.81
209.22

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 2.27
CELG's Price/Projected FCF is ranked higher than
65% of the 182 Companies
in the Global Biotechnology industry.

( Industry Median: 3.56 vs. CELG: 2.27 )
Ranked among companies with meaningful Price/Projected FCF only.
CELG' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.66  Med: 5.62 Max: 122.67
Current: 2.27
1.66
122.67
Price/Median PS Value 0.78
CELG's Price/Median PS Value is ranked higher than
62% of the 736 Companies
in the Global Biotechnology industry.

( Industry Median: 0.92 vs. CELG: 0.78 )
Ranked among companies with meaningful Price/Median PS Value only.
CELG' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.54  Med: 1.35 Max: 30
Current: 0.78
0.54
30
Price/Peter Lynch Fair Value 2.57
CELG's Price/Peter Lynch Fair Value is ranked lower than
66% of the 59 Companies
in the Global Biotechnology industry.

( Industry Median: 1.68 vs. CELG: 2.57 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
CELG' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.36  Med: 1.42 Max: 5.1
Current: 2.57
0.36
5.1
Earnings Yield (Greenblatt) (%) 3.00
CELG's Earnings Yield (Greenblatt) (%) is ranked higher than
83% of the 1100 Companies
in the Global Biotechnology industry.

( Industry Median: -9.50 vs. CELG: 3.00 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CELG' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.6  Med: 2.70 Max: 6.7
Current: 3
0.6
6.7
Forward Rate of Return (Yacktman) (%) 20.75
CELG's Forward Rate of Return (Yacktman) (%) is ranked higher than
63% of the 114 Companies
in the Global Biotechnology industry.

( Industry Median: 14.39 vs. CELG: 20.75 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
CELG' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 0.1  Med: 1.90 Max: 34.8
Current: 20.75
0.1
34.8

More Statistics

Revenue (TTM) (Mil) $9,687
EPS (TTM) $ 2.07
Beta1.61
Short Percentage of Float1.09%
52-Week Range $92.98 - 140.72
Shares Outstanding (Mil)774.60

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 11,145 13,285 15,400
EPS ($) 5.68 7.10 8.90
EPS w/o NRI ($) 5.68 7.10 8.90
EPS Growth Rate
(3Y to 5Y Estimate)
20.19%
» More Articles for CELG

Headlines

Articles On GuruFocus.com
Celgene: Is It a Buy? Jun 21 2016 
5 Attractive Biotechnology Stocks for Healthy Long-term Returns Jun 10 2016 
Gilead and Celgene Among Biotechnology Stocks to Buy May 26 2016 
DISH Network, H&R Block, Celgene, Plum Creek Timber Log Largest Insider Sells Jan 04 2016 
Taking a Look at Barron’s 10 Favorite Stocks for 2016 Dec 07 2015 
Celgene: A Primer on Growth Stock Value Investing - Part 2 Nov 13 2015 
My Top 3 Pharma Stock Picks Jun 09 2015 
10 Reasons Why Growth Stocks Can Be Appropriate for Retired Investors Jun 04 2015 
Big Pharma Companies Are Betting On Regenerative Medicine - Should You? May 26 2015 
Celgene’s Earnings Shine While Revenue Misses By An Inch In The First Quarter May 06 2015 

More From Other Websites
How Does Brexit Affect Biotech Stocks? Wall Street Weighs In Jun 24 2016
After Brexit, These Biotech Stocks Are Vulnerable To A Mighty Dollar Jun 24 2016
Biotech: Buy the Brexit Blowup? Jun 24 2016
Worst Is Yet to Come for Celgene? Jun 22 2016
Pharma stocks are soaring for the first time in weeks because something didn't happen Jun 22 2016
Biotech: Why Take the Risk? Jun 22 2016
Biotechs Highlight Jefferies 4 Top Growth Stocks to Buy Jun 22 2016
The Quest for an Effective Treatment for Pancreatic Cancer Jun 22 2016
Four NCI Cancer Centers Announce Landmark Research Consortium and Collaborations with Celgene Jun 22 2016
Four NCI Cancer Centers Announce Landmark Research Consortium and Collaborations with Celgene Jun 22 2016
Why Biotech is Getting Crushed Jun 21 2016
Celgene: Is It a Buy? Jun 21 2016
5 Of The Hottest Stocks To Own During The Summer Jun 20 2016
Why These Five Stocks Are in Spotlight on Monday Jun 20 2016
Put trade follow downtrend in Celgene Jun 20 2016
This Weekend's Barron's: Penta: Trusted Advice for Those With Assets of $5 Million or More ~ Best... Jun 20 2016
Celgene Announces Additional $3 Billion Share Repurchase Authorization Jun 15 2016
Acceleron and Celgene Announce Updated Results from an Ongoing Phase 2 Study of Luspatercept in... Jun 10 2016
Acceleron and Celgene Announce Updated Results from an Ongoing Phase 2 Study of Luspatercept in... Jun 10 2016
Acceleron and Celgene Announce Updated Results from an Ongoing Phase 2 Study of Luspatercept in... Jun 10 2016
Acceleron and Celgene Announce Updated Results from an Ongoing Phase 2 Study of Luspatercept in... Jun 10 2016
Study Reveals Racial Disparities in Multiple Myeloma Treatment Patterns Jun 07 2016
Celgene Corporation to Webcast at Upcoming Investor Conferences May 20 2016
Celgene Announces Presentations of Investigational Studies in Solid Tumor and Blood Cancers at ASCO... May 18 2016
Agios and Celgene Establish New Collaboration in Metabolic Immuno-Oncology and Amend Certain Rights... May 17 2016
Agios and Celgene Establish New Collaboration in Metabolic Immuno-Oncology and Amend Certain Rights... May 17 2016
Agios and Celgene Establish New Collaboration in Metabolic Immuno-Oncology and Amend Certain Rights... May 17 2016
Celgene Launches Fictional Film, Millefeuille, to Shed New Light on Complex Psoriasis Challenges May 17 2016
Analysis - Pfizer's Anacor deal showcases new wave of eczema therapies May 17 2016
Celgene Reports First Quarter 2016 Operating and Financial Results Apr 28 2016
Celgene beats 1Q profit forecasts Apr 28 2016
Celgene Corporation to Webcast at Upcoming Investor Conferences Apr 27 2016
Celgene and Juno Announce Celgene Exercised Option to Develop and Commercialize CD19-directed... Apr 11 2016
Celgene Corporation to Announce First Quarter 2016 Results on April 28, 2016 Apr 01 2016
Drug distribution becomes weapon to block competition Mar 03 2016
Celgene Corporation to Webcast at Upcoming Investor Conferences Feb 01 2016
Celgene misses 4Q profit forecasts Jan 28 2016
Celgene Reports Fourth Quarter and Full Year 2015 Operating and Financial Results Jan 28 2016
Celgene Corporation Announces 2016 Financial Outlook and Preliminary 2015 Results Jan 11 2016
US STOCKS-On Wall Street, oil proffers modest Santa Claus rally Dec 23 2015
Celgene settles U.S. patent litigation for top seller Revlimid Dec 22 2015
AstraZeneca chases Acerta to secure next cancer drug winner Dec 14 2015
Celgene reports 3Q loss Nov 05 2015
Celgene Corporation to Webcast Upcoming Investor Conferences in September Aug 26 2015
July is now fifth busiest high-grade month on record Jul 31 2015
Celgene beats Street 2Q forecasts Jul 23 2015
Wall Street lauds Celgene's $7.2 billion Receptos buy Jul 15 2015
US STOCKS-Wall St higher; financial stocks lead Jul 15 2015
US STOCKS-Wall St up as Fed says on track to raise rates in 2015 Jul 15 2015
Celgene will buy drug developer Receptos for $7.32 billion Jul 14 2015
Celgene to buy Receptos for $7.2 billion Jul 14 2015
Celgene, Juno map out cancer treatment collaboration Jun 30 2015
Global cancer drug spending hits $100 billion in 2014 - IMS Health May 05 2015
Celgene sales highlight Revlimid dependence ahead of patent ruling Apr 30 2015
Wall Street falls on mixed economic data; Apple weighs Apr 30 2015
US STOCKS-Wall St falls on mixed economic data; Apple weighs Apr 30 2015
Wall Street opens lower as Apple, Celgene weigh Apr 30 2015
US STOCKS-Wall St opens lower as Apple, Celgene weigh Apr 30 2015
Celgene tops 1Q profit forecasts Apr 30 2015
Midday Glance: Biotechnology companies Apr 29 2015
Early Glance: Biotechnology companies Apr 29 2015
Investors seek protection against healthcare stock decline Apr 24 2015
AstraZeneca insists Celgene deal about strategy, not cash Apr 24 2015
AstraZeneca insists Celgene deal about strategy, not cash Apr 24 2015
AstraZeneca looks beyond Nexium hit with new cancer deals Apr 24 2015
Europe gives green light to AbbVie hepatitis C medicine, others Nov 21 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)